Commercial Physical & Biological Research Industry - SEC Form 4 Insider Trading Screener

Services Sector - Engineering, Accounting, Research, Management Services - Commercial Physical & Biological Research
General
Tickers
Insider
Sh Price $
Lqdty M$
Date
Filing Date
  
Trade Date
  
Filing Delay
N Days Ago
Transaction Filing
P - Purchase
S - Sale
A - Grant
D - Sale to Iss
G - Gift
F - Tax
M - Option Ex
X - Option Ex
C - Cnv Deriv
W - Inherited
No deriv Multiple Days
Traded K$
Own Chg %
Industry
Insider Title   Officer
    COB
    CEO
    Pres
    COO
    CFO
    GC
    VP
  Director
  10% Own
  Other
Group by
Sort by
Max Results
Page
clear
100 results - Yahoo - Google - Finviz - Stockcharts - Tradingview - Stocktwits - SEC
TCcnt1d1w1m6m
P22+3+3-6+0
S77+0+1+2+0

X

Filing Date

Trade Date

Ticker

Company

Insider Name

Insider Title

Trade Type 

Share Price

Shares Traded

Shares Owned

Own chg

Value Traded

1d ret

1w ret

1m ret

6m ret

D
2017-04-19
SRNESorrento Therapeutics, Inc.Abg Management Ltd10%P - Purchase$2.00+550,0008,132,536+7%+$1,100,000+6
2017-04-19
SRNESorrento Therapeutics, Inc.Ji HenryPres, CEOP - Purchase$2.00+100,0002,260,869+5%+$200,000+3
D
2017-04-17
PRAHPra Health Sciences, Inc.Baddour LindaEVP, CFOS - Sale+OE$63.59-196,3930-100%-$12,488,631+1
D
2017-04-13
SRNESorrento Therapeutics, Inc.Abg Management Ltd10%P - Purchase$2.00+2,500,0007,582,536+49%+$5,000,000-15-4
2017-04-13
INCYIncyte CorpBienaime Jean JacquesDirP - Purchase$139.66+1,0003,177+46%+$139,6600-2
D
2017-04-07
INCYIncyte CorpStein Steven HEVP, Chief Medical OfficerS - Sale+OE$137.88-32,00014,648-69%-$4,412,310+2-7
D
2017-04-10
INCYIncyte CorpSiegel Eric H.EVP, GCS - Sale+OE$140.18-4,04316,785-19%-$566,748+2-7
D
2017-04-10
INCYIncyte CorpGryska David WEVP, CFOS - Sale+OE$138.00-41,52819,015-69%-$5,730,864+2-7
2017-04-07
INCYIncyte CorpBienaime Jean JacquesDirP - Purchase$139.48+1,0002,177+85%+$139,480+2-7
D
2017-04-03
EXELExelixis, Inc.Marchesi Vincent TDirS - Sale+OE$21.30-10,000120,070-8%-$213,000-4-5
2017-03-31
CASCCascadian Therapeutics, Inc.Myers Scott DunsethPres, CEOP - Purchase$4.11+2,00041,416+5%+$8,229-3+1
D
2017-04-03
EXASExact Sciences CorpCoward D ScottSVP, GCS - Sale+OE$23.74-1,54357,298-3%-$36,631-1+1
D
2017-04-03
INCRInc Research Holdings, Inc.Gaenzle Christopher LCAO, GC, SecS - Sale+OE$45.70-4,73348,317-9%-$216,298-1-2
D
2017-03-31
EXELExelixis, Inc.Wyszomierski Jack LDirS - Sale+OE$21.57-5,15072,960-7%-$111,086-2-6
2017-03-28
CASCCascadian Therapeutics, Inc.Fyfe Gwen A.DirP - Purchase$4.12+1,6663,332+100%+$6,8570-9
D
2017-03-28
PRAHPra Health Sciences, Inc.Shannon ColinPres, CEOS - Sale+OE$64.00-50,0000-100%-$3,200,0000-1
D
2017-03-27
PRAHPra Health Sciences, Inc.Dockhorn David WEVP, CCOS - Sale+OE$62.00-85,1820-100%-$5,281,28400
2017-03-27
EXELExelixis, Inc.Hessekiel JeffreyEVP, GCS - Sale$21.02-6,884267,946-3%-$144,702-10
2017-03-24
SNMXSenomyx IncGray Mary AnnDirP - Purchase$1.00+10,00010,000New+$10,000+2+2
D
2017-03-22
EXELExelixis, Inc.Hessekiel JeffreyEVP, GCS - Sale+OE$20.54-23,787274,830-8%-$488,585+2+1
M
2017-03-22
SNMXSenomyx IncPoyhonen JohnPres, CEOP - Purchase$0.98+50,000158,293+46%+$49,027+1+1-7
2017-03-20
CASCCascadian Therapeutics, Inc.Myers Scott DunsethPres, CEOP - Purchase$3.93+1,00039,416+3%+$3,927+7+13+8
D
2017-03-20
EXELExelixis, Inc.Feldbaum Carl BDirS - Sale+OE$21.77-10,00048,721-17%-$217,7000+4+3
D
2017-03-20
EXELExelixis, Inc.Papadopoulos SteliosDirS - Sale+OE$21.66-10,0001,238,471-1%-$216,6000+4+3
D
2017-03-17
INCYIncyte CorpBrooke Paul ADirS - Sale+OE$147.75-20,000196,756-9%-$2,955,000-5-6-15
DM
2017-03-16
INCYIncyte CorpFriedman Paul ADirS - Sale+OE$148.72-50,000297,518-14%-$7,436,164-5-6-15
D
2017-03-15
EXELExelixis, Inc.Willsey LanceDirS - Sale+OE$22.86-10,000568,273-2%-$228,6000-8-3
D
2017-03-15
EXELExelixis, Inc.Schwab GiselaPres Prod Dev, Med Aff, CMOS - Sale+OE$22.53-50,007172,027-23%-$1,126,6580-8-3
2017-03-06
BHRTU.S. Stem Cell, Inc.Murphy William P JrDirP - Purchase$0.02+1,200,0001,564,039+330%+$24,000
D
2017-03-16
CRLCharles River Laboratories International IncMolho DavideCorporate EVPS - Sale+OE$90.00-11,71763,566-16%-$1,054,530+1-2-2
2017-03-13
EXELExelixis, Inc.Cohen CharlesDirS - Sale$21.82-10,000238,180-4%-$218,200+5+1-4
2017-03-13
EXASExact Sciences CorpLidgard Graham PeterChief Science OfficerS - Sale$21.16-2,945343,170-1%-$62,3160+1+9
2017-03-13
EXASExact Sciences CorpCoward D ScottSVP, GCS - Sale$21.16-1,98354,153-4%-$41,9600+1+9
2017-03-13
EXASExact Sciences CorpConroy Kevin TPres, CEOS - Sale$21.16-12,059907,418-1%-$255,1680+1+9
2017-03-13
EXASExact Sciences CorpArora ManeeshCOOS - Sale$21.16-5,574634,537-1%-$117,9460+1+9
2017-03-10
CRLCharles River Laboratories International IncMolho DavideCorporate EVPS - Sale$89.71-3,19169,781-4%-$286,2540+1-3
2017-03-10
CRLCharles River Laboratories International IncJohst David PCorporate EVPS - Sale$89.44-7,307181,255-4%-$653,5400+1-3
D
2017-03-10
CRLCharles River Laboratories International IncJohst David PCorporate EVPS - Sale+OE$89.06-34,593188,562-16%-$3,080,9320+1-3
D
2017-03-10
EXELExelixis, Inc.Marchesi Vincent TDirS - Sale+OE$21.98-40,000120,070-25%-$879,200+1+1-5
D
2017-03-03
EXELExelixis, Inc.Hessekiel JeffreyEVP, GCS - Sale+OE$23.04-100,000246,617-29%-$2,303,678-2-2-4
DM
2017-03-03
EXELExelixis, Inc.Morrissey MichaelPres, CEOS - Sale+OE$22.72-200,000249,523-44%-$4,544,000-2-2-4
2017-03-03
EXELExelixis, Inc.Haley Patrick J.SVP, CommercialS - Sale$23.04-2,500140,400-2%-$57,600-2-2-4
2017-03-06
CRLCharles River Laboratories International IncBarbo William DCorporate EVP, CCOS - Sale$87.90-1,90020,924-8%-$167,014+1+10
D
2017-03-06
CRLCharles River Laboratories International IncBarbo William DCorporate EVP, CCOS - Sale+OE$87.78-12,54822,824-35%-$1,101,409+1+2+1
2017-03-03
CRLCharles River Laboratories International IncSmith David RossCorporate EVP, CFO, CAOS - Sale$88.12-3,89013,495-22%-$342,805+1+2+1
D
2017-03-03
CRLCharles River Laboratories International IncSmith David RossCorporate EVP, CFO, CAOS - Sale+OE$87.94-7,75017,385-31%-$681,531+1+2+1
D
2017-03-03
PRXLParexel International CorpPretorius SybrandSVP, Chief Scientific OfficerS - Sale+OE$65.12-8,0501,900-81%-$524,216-10-4
D
2017-03-03
INCRInc Research Holdings, Inc.Macdonald AlistairCEOS - Sale+OE$45.00-8,82874,468-11%-$397,260-10+1
2017-03-03
EXELExelixis, Inc.Senner Christopher J.EVP, CFOS - Sale$22.80-11,000102,181-10%-$250,800-2-5-6
D
2017-03-01
EXELExelixis, Inc.Lamb PeterEVP, Scientific Strategy, CSOS - Sale+OE$22.19-45,00089,728-33%-$998,550-2-5-6
DM
2017-03-01
EXELExelixis, Inc.Poste GeorgeDirS - Sale+OE$22.53-76,25077,555-50%-$1,718,185-2-5-6
2017-03-01
CRLCharles River Laboratories International IncBertolini Robert JDirS - Sale$88.00-6,73520,150-25%-$592,7020+2+2
D
2017-03-01
CRLCharles River Laboratories International IncBertolini Robert JDirS - Sale+OE$87.53-5,25526,885-16%-$459,9880+2+2
2017-02-27
INCYIncyte CorpHuber Reid MEVP, Chief Scientific OfficerS - Sale$131.88-2,00852,262-4%-$264,81500+5
2017-02-28
CRLCharles River Laboratories International IncFoster James CCOB, Pres, CEOS - Sale$88.48-1,270376,0180%-$112,375+1+1+3
2017-02-28
CRLCharles River Laboratories International IncFoster James CCOB, Pres, CEOS - Sale$88.03-3,772383,000-1%-$332,064+1+1+3
2017-02-28
CRLCharles River Laboratories International IncFoster James CCOB, Pres, CEOS - Sale$87.61-5,081386,772-1%-$445,167+1+1+3
2017-02-28
CRLCharles River Laboratories International IncFoster James CCOB, Pres, CEOS - Sale$87.31-5,038391,853-1%-$439,887+1+1+3
D
2017-02-28
CRLCharles River Laboratories International IncFoster James CCOB, Pres, CEOS - Sale+OE$87.09-4,910396,891-1%-$427,615+1+1+3
DM
2017-02-24
EXASExact Sciences CorpLidgard Graham PeterChief Science OfficerS - Sale+OE$21.51-8,668337,690-3%-$186,429+3+2+6
D
2017-02-27
EXASExact Sciences CorpCoward D ScottSVP, GCS - Sale+OE$21.48-7,04650,111-12%-$151,348+3+2+6
DM
2017-02-24
EXASExact Sciences CorpConroy Kevin TPres, CEOS - Sale+OE$21.51-27,134895,077-3%-$583,520+3+2+6
DM
2017-02-24
EXASExact Sciences CorpArora ManeeshCOOS - Sale+OE$21.50-11,114628,836-2%-$238,968+3+2+6
D
2017-02-23
INCYIncyte CorpFriedman Paul ADirS - Sale+OE$120.32-50,000297,518-14%-$6,016,000-1+2+4
2017-02-22
CRLCharles River Laboratories International IncFoster James CCOB, Pres, CEOS - Sale$88.22-3,404376,855-1%-$300,300000
2017-02-22
CRLCharles River Laboratories International IncFoster James CCOB, Pres, CEOS - Sale$87.84-8,658369,919-2%-$760,562000
D
2017-02-22
CRLCharles River Laboratories International IncFoster James CCOB, Pres, CEOS - Sale+OE$87.64-9,717378,577-3%-$851,592000
DM
2017-02-21
PRAHPra Health Sciences, Inc.Shannon ColinPres, CEOS - Sale+OE$61.50-100,0000-100%-$6,150,000-1-3-2
2017-02-22
SRNESorrento Therapeutics, Inc.Ji HenryPres, CEOP - Purchase$5.60+2,0002,160,8690%+$11,200-1-1-21
D
2017-02-17
NRCIANational Research CorpHays Michael D.CEO, 10%S - Sale+OE$17.45-500,0007,362,341-6%-$8,725,000+2+9+11
D
2017-02-14
PRXLParexel International CorpBatt Douglas ASVP, GC, Sec.S - Sale+OE$65.39-5,50061,479-8%-$359,645-1-2-6
D
2017-02-14
CRLCharles River Laboratories International IncMilne George M JrDirS - Sale+OE$86.52-10,71029,530-27%-$926,6290-10
A
2017-02-10
SRNESorrento Therapeutics, Inc.Ji HenryPres, CEOP - Purchase$5.15+20,00037,776+113%+$103,000+2+2-21
D
2017-02-09
PRXLParexel International CorpSaarony GadiSVP, CRSS - Sale+OE$64.54-2,32511,883-16%-$150,0560+4+2
D
2017-02-01
EXELExelixis, Inc.Lamb PeterEVP, Scientific Strategy, CSOS - Sale+OE$18.65-70,00089,680-44%-$1,305,500-1+12+13
2017-02-03
SRNESorrento Therapeutics, Inc.Wu Yue AlexanderDirP - Purchase$5.15+5,0005,000New+$25,750+8+8-6
2017-02-03
SRNESorrento Therapeutics, Inc.Janda KimDirP - Purchase$5.15+3,0003,000New+$15,450+8+8-6
2017-02-03
SRNESorrento Therapeutics, Inc.Su JeffreyEVP, COOP - Purchase$5.15+4,00013,000+44%+$20,600+8+8-6
2017-02-03
SRNESorrento Therapeutics, Inc.Herde KevinEVP, CFOP - Purchase$5.15+3,0007,000+75%+$15,450+8+8-6
2017-02-03
SRNESorrento Therapeutics, Inc.Ji HenryPres, CEOP - Purchase$5.15+20,0002,158,869+1%+$103,000+8+8-6
2017-02-03
SRNESorrento Therapeutics, Inc.Ng George KSee RemarksS - Sale$5.15-40,00064,239-38%-$206,000+8+8-6
2017-02-03
SRNESorrento Therapeutics, Inc.Shah JaisimDirP - Purchase$5.15+10,000102,631+11%+$51,500+8+8-6
2017-02-03
SRNESorrento Therapeutics, Inc.Zeldis Jerome BSee RemarksP - Purchase$5.15+10,00010,000New+$51,500+8+8-6
2017-02-02
CASCCascadian Therapeutics, Inc.Love Ted WDirP - Purchase$4.24+23,00027,209+546%+$97,520+4+1-3
2017-01-30
CASCCascadian Therapeutics, Inc.Henney Christopher SDirP - Purchase$4.11+25,32450,000+103%+$103,973+300
D
2017-01-30
CRLCharles River Laboratories International IncJohst David PCorporate EVPS - Sale+OE$78.00-13,950160,746-8%-$1,088,100+1+2+8
2017-01-27
CASCCascadian Therapeutics, Inc.Myers Scott DunsethPres, CEOP - Purchase$3.76+20,50038,416+114%+$77,039+2+7+3
M
2017-01-27
LUNALuna Innovations IncCarilion Health System10%S - Sale$1.99-84,5662,164,330-4%-$167,944-1+4-6
2017-01-20
INCRInc Research Holdings, Inc.Gaenzle Christopher LCAO, GC, SecS - Sale$50.09-1,18639,037-3%-$59,4060+4+8
DM
2017-01-20
INCRInc Research Holdings, Inc.Rush Gregory SEVP, CFOS - Sale+OE$50.57-2,90744,209-6%-$147,0040+4+8
2017-01-20
INCRInc Research Holdings, Inc.Macdonald AlistairCEOS - Sale$50.50-1,37552,854-3%-$69,4380+4+8
DM
2017-01-13
NRCIANational Research CorpHays Michael D.CEO, 10%S - Sale+OE$18.48-14,2967,862,3410%-$264,202-10-3
D
2017-01-11
NRCIANational Research CorpHays Michael D.CEO, 10%S - Sale+OE$19.00-7007,876,6370%-$13,3000-2-1
2017-01-09
INCYIncyte CorpHuber Reid MEVP, Chief Scientific OfficerS - Sale$113.55-11,73952,185-18%-$1,332,963+20+6
DM
2017-01-06
NRCIANational Research CorpHays Michael D.CEO, 10%S - Sale+OE$19.24-5,4827,877,3370%-$105,467-2-5-7
D
2017-01-05
INCRInc Research Holdings, Inc.Macdonald AlistairCEOS - Sale+OE$52.19-14,84054,229-21%-$774,440+1-2+1
D
2017-01-03
EXELExelixis, Inc.Lamb PeterEVP, Scientific Strategy, CSOS - Sale+OE$14.65-70,00089,624-44%-$1,025,636+2+21+34
D
2017-01-03
EXASExact Sciences CorpCoward D ScottSVP, GCS - Sale+OE$13.61-1,53534,918-4%-$20,891+2+25+28
D
2017-01-03
INCRInc Research Holdings, Inc.Gaenzle Christopher LCAO, GC, SecS - Sale+OE$51.90-15,38341,300-27%-$798,4200+1+2
D
2017-01-03
INCRInc Research Holdings, Inc.Rush Gregory SEVP, CFOS - Sale+OE$51.90-41,42047,209-47%-$2,149,8180+1+2

AAmended filing
DDerivative transaction in filing (usually option exercise)
EError detected in filing
MMultiple transactions in filing; earliest reported transaction date and weighted average transaction price
S - SaleSale of securities on an exchange or to another person
S - Sale+OESale of securities on an exchange or to another person (after option exercise)
F - TaxPayment of exercise price or tax liability using portion of securities received from the company
P - PurchasePurchase of securities on an exchange or from another person
Return to top